Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRS Antares Pharma	$5.59	$5.59	$3.11 ▼ $5.60	$955.06M	1.15	3.29 million shs	6 shs
KIDS OrthoPediatrics	$22.14 +1.1%	$21.55	$19.52 ▼ $35.99	$537.78M	1.1	198,592 shs	92,601 shs
LMAT LeMaitre Vascular	$84.09 +0.5%	$82.72	$71.42 ▼ $109.58	$1.90B	0.82	169,831 shs	73,227 shs
XENT Intersect ENT	$28.24	$28.24	$15.92 ▼ $28.25	$954.91M	1.45	351,526 shs	14,512 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRS Antares Pharma	0.00%	0.00%	0.00%	0.00%	0.00%
KIDS OrthoPediatrics	0.00%	-2.56%	+3.45%	+4.34%	-33.16%
LMAT LeMaitre Vascular	0.00%	-0.87%	+3.14%	-0.12%	-2.75%
XENT Intersect ENT	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATRS Antares Pharma	1.8752 of 5 stars	0.0	0.0	0.0	3.6	0.6	0.8	3.1
KIDS OrthoPediatrics	4.2858 of 5 stars	3.4	2.0	0.0	3.9	2.7	3.3	0.6
LMAT LeMaitre Vascular	2.2772 of 5 stars	2.2	1.0	3.3	0.0	1.6	2.5	1.3
XENT Intersect ENT	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATRS Antares Pharma	0.00	N/A	N/A	N/A
KIDS OrthoPediatrics	2.83	Moderate Buy	$35.83	61.85% Upside
LMAT LeMaitre Vascular	2.33	Hold	$97.83	16.34% Upside
XENT Intersect ENT	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest LMAT, ATRS, XENT, and KIDS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/8/2025	KIDS OrthoPediatrics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $30.00
5/8/2025	KIDS OrthoPediatrics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00

(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATRS Antares Pharma	$183.98M	5.19	$0.13 per share	43.89	$1.03 per share	5.43
KIDS OrthoPediatrics	$204.73M	2.63	N/A	N/A	$14.64 per share	1.51
LMAT LeMaitre Vascular	$226.26M	8.40	$2.40 per share	35.03	$15.00 per share	5.61
XENT Intersect ENT	$106.75M	8.95	N/A	N/A	($2.06) per share	-13.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATRS Antares Pharma	$46.29M	$0.24	23.29	25.41	N/A	21.90%	7.43%	4.92%	N/A
KIDS OrthoPediatrics	-$37.82M	-$1.75	N/A	N/A	N/A	-19.15%	-7.03%	-5.45%	8/4/2025 (Estimated)
LMAT LeMaitre Vascular	$44.04M	$1.98	42.47	38.75	2.21	19.96%	13.53%	9.78%	8/5/2025 (Estimated)
XENT Intersect ENT	-$159.63M	-$4.79	N/A	N/A	N/A	-161.94%	-709.52%	-48.18%	N/A

Latest LMAT, ATRS, XENT, and KIDS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	LMAT LeMaitre Vascular	$0.57	N/A	N/A	N/A	$62.48 million	N/A
8/4/2025	Q2 2025	KIDS OrthoPediatrics	-$0.17	N/A	N/A	N/A	$61.40 million	N/A
5/7/2025	Q1 2025	KIDS OrthoPediatrics	-$0.26	-$0.39	-$0.13	-$0.46	$51.68 million	$52.41 million
5/1/2025	Q1 2025	LMAT LeMaitre Vascular	$0.50	$0.48	-$0.02	$0.48	$57.61 million	$59.87 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATRS Antares Pharma	N/A	N/A	N/A	N/A	N/A
KIDS OrthoPediatrics	N/A	N/A	N/A	N/A	N/A
LMAT LeMaitre Vascular	$0.80	0.95%	N/A	40.40%	14 Years
XENT Intersect ENT	N/A	N/A	N/A	N/A	N/A

Latest LMAT, ATRS, XENT, and KIDS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/29/2025	LMAT LeMaitre Vascular	quarterly	$0.20	1%	5/15/2025	5/15/2025	5/29/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATRS Antares Pharma	0.10	3.08	2.87
KIDS OrthoPediatrics	0.21	6.19	2.99
LMAT LeMaitre Vascular	0.48	16.49	13.83
XENT Intersect ENT	6.89	1.88	1.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATRS Antares Pharma	50.41%
KIDS OrthoPediatrics	69.05%
LMAT LeMaitre Vascular	84.64%
XENT Intersect ENT	92.47%

Insider Ownership

Company	Insider Ownership
ATRS Antares Pharma	5.90%
KIDS OrthoPediatrics	31.80%
LMAT LeMaitre Vascular	9.50%
XENT Intersect ENT	2.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATRS Antares Pharma	201	170.85 million	160.77 million	Optionable
KIDS OrthoPediatrics	200	24.29 million	16.56 million	Optionable
LMAT LeMaitre Vascular	490	22.59 million	20.45 million	Optionable
XENT Intersect ENT	433	33.81 million	33.10 million	Optionable

LMAT, ATRS, XENT, and KIDS Headlines

Recent News About These Companies

Zee Ent. - Zee Entertainment Enterprises Share Price

August 2, 2024 | economictimes.indiatimes.com

Kiatnakin Bank PCL (KKP)

July 26, 2024 | investing.com

At the Intersection of Law & Policy

March 1, 2024 | slu.eduS

74-year-old woman killed in east Charlotte crash, CMPD says

December 6, 2023 | wsoctv.comW

What 4 Execs Want People To Know About the Intersection Between the Justice System and Behavioral Health

November 29, 2023 | medcitynews.comM

Traffic signal installed at notorious Riverside intersection where crash killed 8-year-old

November 4, 2023 | nbclosangeles.comN

Rogue Robotaxi Tries To Drive Down Footpath, Reverses Into Intersection

October 30, 2023 | jalopnik.comJ

XENT Historical Data

October 21, 2023 | investing.com

Video shows Brightline train goes through intersection while bars up; officials explain why

October 5, 2023 | tcpalm.comT

Intersection Into Proposed Cricket Stadium OK'd By Kendall Board

September 26, 2023 | patch.com

Music At The Intersection Festival Tells St. Louis’ Rich Musical History

September 12, 2023 | yahoo.com

4-way stop coming to Poinciana intersection where crash killed 4

September 12, 2023 | clickorlando.comC

Weaver intersection to finally open, Plainview close as extension work continues

September 9, 2023 | news-leader.comN

More social space, less traffic noise: The award-winning reno on a busy intersection

September 2, 2023 | smh.com.au

Code of conduct prepared for peace, intersect harmony during Muharram: Ayaz

August 31, 2023 | radio.gov.pkR

Euclid looking to increase safety at intersection following study

August 28, 2023 | news-herald.comN

Cruise car reportedly swerves in backhoe's way, is busted in SF intersection

August 28, 2023 | sfgate.com

Toronto is about to get a new type of intersection unlike any it's seen before

August 27, 2023 | blogto.comB

Watch: US Woman Points Gun At Cars On Intersection, Cop Drives Cruiser Into Her

August 19, 2023 | ndtv.comN

Lawsuit claims Iowa City teens were 'drag racing' when they struck Jennifer Russell's car in an intersection

July 19, 2023 | press-citizen.comP

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
By Leo Miller | June 28, 2025
View Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?

LMAT, ATRS, XENT, and KIDS Company Descriptions

Antares Pharma NASDAQ:ATRS

Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey.

OrthoPediatrics NASDAQ:KIDS

$22.14 +0.25 (+1.14%)

Closing price 04:00 PM Eastern

Extended Trading

$22.14 0.00 (0.00%)

As of 04:10 PM Eastern

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediguard, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIMTM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIROTM Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, and Mitchell Ponseti. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.

LeMaitre Vascular NASDAQ:LMAT

$84.09 +0.40 (+0.48%)

Closing price 04:00 PM Eastern

Extended Trading

$84.09 0.00 (0.00%)

As of 04:55 PM Eastern

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

Intersect ENT NASDAQ:XENT

Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time